An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of Adebrelimab Plus Apatinib as Adjuvant Therapy in Participants With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection
Latest Information Update: 06 Aug 2024
At a glance
- Drugs Adebrelimab (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Jun 2024 New trial record